Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma

Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma

Abstract Background and Aim Molecular‐targeted therapies such as sorafenib and lenvatinib have long been used as first‐line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known a...

Full description

Bibliographic Details
Main Authors: Yoshihiko Yano, Atsushi Yamamoto, Akihiro Minami, Kenji Momose, Takuya Mimura, Soo Ki Kim, Hiroki Hayashi, Takuo Kado, Hirotaka Hirano, Seiya Hirohata, Seitetsu Yoon, Katsuhisa Nishi, Hiroshi Tei, Hidenori Tanaka, Sachiko Oouchi, Takanori Matsuura, Eiichiro Yasutomi, Yuri Hatazawa, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama, Kobe Liver Conference (KLC)
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:JGH Open
Subjects:
hepatocellular carcinoma
post‐progression therapy
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/jgh3.12772

Internet

https://doi.org/10.1002/jgh3.12772

Similar Items